Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer CellsAnnette S. Little, Simon J. Cook, Kathryn Balmanno et al.|Science Signaling|2011Cited by 209
A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. CookAnnette S. Little, Simon J. Cook, Mark Hampson et al.|Science Signaling|2011Cited by 44
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055Gayle Marshall, Sylvie M. Guichard, Zoë Howard et al.|Biochemical Society Transactions|2011Cited by 38
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerVladimir Lazar, Jean‐Yves Blay, Eitan Rubin et al.|Oncotarget|2015Cited by 31
157 The mTOR kinase inhibitor AZD8055 induces cell death in Her2+ tumours partially or intrinsically resistant to ErbB2 inhibitorsSarah V. Holt, Sylvie M. Guichard, Gayle Marshall et al.|European Journal of Cancer Supplements|2010Cited by 1